Prostaglandin (PG) D 2 is the ligand for the G-protein coupled receptors DP1 (D-type prostanoid receptor 1) and DP2 (also known as chemoattractant receptor homologous molecule, expressed on Th2 cells; CRTH2). Both, DP1 and DP2 are expressed on the cellular surface of eosinophils;
in tissue damage. Eosinophils are considered as crucial effector cells in chronic allergic inflammation since they are involved in increasing epithelial-to-mesenchymal transition, 2,3 thickening of airway walls, airway hyperresponsiveness, and angiogenesis. 4, 5 Therefore, eosinophils are of major therapeutic interest in allergic diseases.
Concomitant with allergic inflammation, the life span of immune cells such as macrophages, Th2 cells, or eosinophils is known to be prolonged. 6 Accordingly, blocking the prominent pro-survival cytokine IL-5 using the monoclonal antibodies mepolizumab or reslizumab profoundly reduced eosinophil numbers and effectively prevented exacerbations in cases of severe, highly eosinophilic asthma. [7] [8] [9] This demonstrated that targeting mechanisms that regulate eosinophil survival is a clinically relevant approach in allergic diseases. PGD 2 is the major lipid mediator released by mast cells following crosslinking of allergen-specific IgE molecules displayed on their surface in sensitized individuals as part of the early allergic reaction. 10, 11 Furthermore, eosinophils, dendritic cells, macrophages, and endothelial cells 12 produce PGD 2 and substantial amounts have been detected in tissues affected by allergic reactions, such as lung, 13 skin, 14, 15 and esophagus . 16 PGD 2 is the ligand for two 7-transmembrane G proteincoupled receptors, named D-type prostanoid (DP) receptor 1 and chemoattractant receptor homologous molecule expressed on Th2 cells (CRTH2, also termed DP2), 17 that are co-expressed on the cell surface of eosinophils. 18 Although DP1 and DP2 bind PGD 2 with similar avidity, 17 DP2 shares greater homology with classical chemoattractant receptors (e.g., BLT1/2, C5a-R1, CCR3, FPR) than with other prostanoid receptors. 19, 20 PGD 2 and selective DP2 agonists cause chemotaxis and proinflammatory activation of eosinophils including cellular responses, such as Ca 2+ flux, CD11b upregulation, respiratory burst, and eosinophil cationic protein release, 20-23 via binding to DP2. In contrast, the functional responses and exact signaling pathways triggered by DP1 activation in eosinophils have remained unclear up to now. We have previously shown in eosinophils and heterologous expression systems that the DP1 receptor augments the signaling and functionality of the DP2 receptor, including intracellular Ca 2+ flux, chemotaxis, and oxidative burst. 18, 24, 25 Defining the role of DP1 on eosinophils might hence contribute to the full understanding of the role of PGD 2 in allergic disease and asthma and explain the limited efficacy of DP2 antagonists in clinical studies. 12 One single report described that activation of DP1 on eosinophils protected them from undergoing apoptosis 21 ; whether this resulted in extended life-span of eosinophils and was due to activation of pro-survival signaling pathways has still remained unresolved. Another study, however, presented opposing data arguing for a pro-apoptotic effect of higher concentrations (10 M) of PGD 2 that was attributed to inhibition of IkB degradation in eosinophils by the PGD 2 metabolites 15-deoxy-PGJ 2 and Δ 12 -PGJ 2 . 26 In order to unequivocally decipher the role of PGD 2 and its receptors in the regulation of eosinophil survival, this study investigated how DP1 regulates eosinophil survival and operates as a transcriptional regulator in a pro-inflammatory setting. Thus, we propose that DP1
antagonists could have beneficial effects by accelerating the resolution of allergic inflammation.
METHODS

Materials
Prostaglandin D 2 receptor agonists PGD 2 , BW245c, 13,14-di-hydro 15-keto PGD 2 (DK-PGD 2 ), and antagonists MK0524, Cay10471, and BW A868c were purchased from Cayman, Ann Arbor, USA, and rosiglitazone, BH3I-1, and HA14.1 were purchased from Sigma-Aldrich, St.
Louis, USA.
Preparation of human peripheral blood eosinophils
Human eosinophils were isolated from blood samples of healthy volunteers according to a protocol approved by the Institutional Review
Board of the Medical University of Graz or Cincinnati Children's
Hospital Medical Center as previously described. 27 In brief, erythrocytes were removed by dextran sedimentation and polymorphonuclear leukocytes were separated from mononuclear cells by density gradient centrifugation (Histopaque 1077, Sigma-Aldrich). Eosinophils were separated from neutrophils in the polymorphonuclear leukocyte fraction by negative magnetic selection using the MACS cell separation system (Eosinophil Isolation Kit, Milteny Biotech, Bergisch Gladbach, Germany) with a resulting purity of typically ≥98%. 
Human embryonic kidney cells
Reporter gene assays
Annexin V/propidium iodide co-staining
Determination of mitochondrial integrity
Eosinophils were incubated with the potential-dependent JC-1 dye (5 g/ml) (Sigma-Aldrich) for 20 min at 37 • C. 
Cell viability assay
HEK-DP2+DP1, HEK-DP1, and HEK-DP2 cells were seeded in 96well
plates at a density of 3 × 10 5 cells/ml and grown to confluence. Subsequently, cells were starved (OptiMEM, Thermo Fisher Scientific), treated with indicated concentrations of PGD 2 and viability was determined as previously described using the CellTiter 96 R AQueous One Solution Cell Proliferation Assay (Promega; Madison, WI, USA) 30 at 24 and 48 h of PGD 2 treatment. 
Caspase 3/7 Glo assay
Electric cell-substrate impedance sensing
Growth performance of HEK-DP2+DP1, HEK-DP1, and HEK-DP2 was monitored using the electric cell-substrate impedance sensing (ECIS) system (Applied Biophysics, Troy, NY, USA). Cells (3 × 10 4 cells/well) were seeded in gelatin coated 96W1E + polycarbonate arrays equipped with gold microelectrodes and allowed to settle overnight. Medium was changed to serum free (OptiMEM) medium 2 h prior to treatment with vehicle, PGD 2 (0.1-10 M) or FBS (10%).
Impedance was measured at 4000 Hz and monitored continuously over ≥60 h.
Microscopy
HEK-DP2+DP1, HEK-DP1, and HEK-DP2 cells were seeded in 96-well plates at a density of 3 × 10 5 cells/ml and grown to confluency. Subsequently, cells were starved (OptiMEM) and treated with indicated 
Gene expression analysis
Flow cytometric analysis of CCR3 and VLA-4 expression
Statistical analysis
Data are shown as means ± SEM or as individual data values. Statistical analysis was carried out with Graph Pad Prism R 7 (GraphPad Software, Inc. CA, USA). Differences between groups were tested by one-way or two-way ANOVA followed by Dunnett's, Tukey's, or Sidak's posttest. P values ≤ 0.05 were considered significant and are indicated as *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; and ****P ≤ 0.0001. 
DP1 -but not DP2 activation promotes survival of eosinophils
We first tested the potential pro-survival effect of the two PGD 2 receptors DP1 and DP2 on eosinophils under ex vivo culture conditions. Isolated peripheral blood eosinophils were cultured in media containing 1% FBS for 18 h. Concurrently, eosinophils were treated with 1 M of PGD 2 , the selective DP1 agonist BW245c, the selective DP2 agonist DK-PGD 2 , or IL-5 [100 pM]. IL-5 is well known for its pro-survival stimulus on eosinophils. 32 The specific DP1 agonist BW245c significantly enhanced the per- Of the BW245c treated eosinophils 50% were viable, 25% earlyand 15% late-apoptotic, and 6% were necrotic after 18 h. IL-5 treatment led proportionally to a similar result with a slightly more pronounced effect on the increase of live cells (59% viable, 20% early-, 13% late-apoptotic, 8% necrotic eosinophils). Annexin V/PI staining at 0 and 3 h revealed that at these early time points there were no significant differences between these treatment groups (data not shown).
We conclude that activation of the DP1 receptor functions as a prosurvival stimulus for eosinophils and reduces the portion of Annexin V + and PI + cell populations.
DP1 signaling enhances eosinophil survival by inhibiting the intrinsic apoptosis pathway
Since the DP1 agonist BW245c prolonged the survival of eosinophils, we aimed to identify the pro-survival signals that were induced by DP1 receptor activation and to assess whether this function of PGD 2 included the activation of programmed cell death pathways. Therefore, we investigated the potential involvement of DP1-mediated signaling PGD 2 is a short-lived molecule that can rapidly be metabolized to J-metabolites such as 15-deoxy-Δ 12, Δ 14 -PGJ 2 (15dPGJ 2 ), which has been reported to have a higher affinity for DP2 than DP1. 17 15dPGJ 2 also activates the intracellular peroxisome proliferatoractivated receptor (PPAR)-at micromolar concentrations, thereby inducing apoptosis of eosinophils. 34 In our hands, 1 M of 15dPGJ 2 significantly increased caspase 3/7 activity in a PPAR--independent manner, since 1 M of the PPAR T0070907 antagonist did not reverse the 15dPGJ 2 -induced caspase 3/7 activation. Moreover, the PPARagonist rosiglitazone (1 M) did not mimic the 15dPGJ 2 -induced caspase activation (Fig. 2D ). T0070907 had no effect on basal caspase 3/7 activity.
BW245c, PGD 2 and IL-5 protect eosinophils from mitochondrial membrane depolarization
Mitochondrial membrane depolarization is an early step of the intrinsic apoptotic cascade and can be determined by staining cells with
ΔΨm-dependent fluorescent dye JC-1, whose fluorescent characteristics depend on the integrity of the mitochondrial membrane potential (ΔΨm). In cells with intact ΔΨm the dye binds and forms J-aggregates at the mitochondrial membrane, and emits light at 590 nm after excitation at 527 nm. Due to the low ΔΨm in early apoptotic cells J-aggregate formation is prevented and allows JC-1 to be present in its monomeric form which emits light at 527 nm. 35 Therefore, this initiating step in the onset of the intrinsic apoptotic cascade can be detected by the loss of fluorescence intensity at 590 nm. Indeed, a smaller proportion of eosinophils showed a depolarized mitochondrial membrane when cultured for 18 h in presence of PGD 2 (22%), BW245c (18%), or IL-5 (20%) compared to vehicle-treated eosinophils (37%). The mitochondrial uncoupler CCCP was added to the cells for the last 30 min of culture and was used as a control for collapsed ΔΨm (Fig. 3A and B ). DK-PGD 2 did not have a significant impact on mitochondrial membrane depolarization of eosinophils.
Additionally, eosinophils incubated with PGD 2 , BW245c, or IL-5
showed more intense staining of intact mitochondria than vehicletreated cells when identified by mitochondria-selective probes (MitoTracker Red CMXRos), which selectively accumulate and are oxidized at the mitochondrial membranes with intact membrane potential ( Fig. 3C ). 
DP1 receptor expression facilitates increased viability of PGD 2 -treated HEK293 cells
Because eosinophils naturally expressed both, DP1 and DP2 receptors we used a HEK293 cell system, with stably overexpressed DP1, DP2, or Next, we assessed the growth of HEK293 monolayers expressing DP1 and/or DP2 that were treated with PGD 2 (0.1-10 M), or 10% FBS as positive control stimulus. PGD 2 increased the growth rate of HEK-DP1 and HEK-DP2+DP1 but not HEK-DP2 at day 2 ( Fig. 6B) as assessed by ECIS. The increase in resistance has been shown to directly correlate with the growth rate of adherent cells. 39 Thus, besides promoting viability, in cells capable of proliferating DP1 receptor expression leads to increased growth in response to PGD 2 . Although PGD 2 did not change the resistance of HEK-DP2, we observed an increased basal resistance of HEK-DP2 when compared to HEK-DP1 or HEK-DP2+DP1. This was probably consistent with faster proliferation of this cell line which we also observed during cell culture handling (Supplementary Fig. 4 ). In a reporter gene assay, DP1 but not DP2 was capable of inducing SRE activation in HEK-DP1 and HEK-DP2+DP1 cells (Fig. 7A) . In contrast, no SRE activation was observed in HEK-DP2 cells. Remarkably, however, the potency of BW245c to activate SRE was reduced when DP2 was co-expressed ( Fig. 7B ). Although the DP2 agonist DK-PGD 2 was unable to induce SRE in HEK-DP1+DP2 cells (Fig. 7C ), blocking DP2 with the specific antagonist Cay10471 led to reduced potency of PGD 2 and BW245c to induce SRE (Fig. 7D-E) 
DP1 but not DP2 is a transcriptional regulator and induces serum response element
Gene expression in eosinophils is regulated by DP1
The transcription factor SRF regulates actin cytoskeleton remodeling, cell contact maintenance and adhesion [44] [45] [46] and was shown to promote the expression of anti-apoptotic Bcl-X L (B-cell lymphomaextra-large) and Bcl-2 (B-cell lymphoma 2). 46 Thus, we tested whether DP1-mediated signaling can affect eosinophil expression of Bcl-X L and the major chemokine receptor, CCR3, and adhesion molecule, VLA-4.
Eosinophils were treated with PGD 2 receptor agonists or IL-5 10 ng/ml for 3 h (RPMI 1% FBS, 37 • C, 5% CO 2 ), total RNA was extracted from cell lysates and mRNA expression was analyzed by qRT-PCR. Indeed, BW245c significantly increased both, mRNA levels and protein surface expression of VLA-4 and CCR3 in human eosinophils, while DK-PGD 2 was ineffective in altering the levels of expression ( Fig. 8A and B) . Similar, BW245c increased mRNA levels of Bcl-X L but did not enhance the level of protein expression significantly as shown by intracellular flow cytometry staining ( Supplementary Fig. 5A and B) .
The ratio of pro-apoptotic BAX to anti-apoptotic Bcl-2 or Bcl-X L reflects the pro-survival or pro-apoptotic status of a cell and can predict whether programmed cell death has been initiated or not. A ratio of BCL-2 to BAX above 1 was shown to correlate with caspase 3 activation whereas a low value (<1) has been described for cells where the onset of apoptosis is suppressed, e.g., in cancer cells. 47 Here, IL-5 significantly decreased the BAX/Bcl-X L ratio in eosinophils whereas BW245c moderately lowered the mean ratio to a value below 1 ( Supplementary Fig. 6 ).
Thus, we conclude that activation of DP1 contributes to a pro-inflammatory status by enhancing VLA-4 and CCR3 expression and delays the onset of apoptosis in eosinophils by enhancing
Bcl-X L expression.
DISCUSSION
In the present study, we report a mechanism through which the PGD 2 receptor DP1 leads to a prolonged survival of human eosinophils. In cells. 51, 52 In contrast, PGD 2 induces apoptosis in human osteoclasts, 53 leukemia cells 54 and non-small cell lung carcinoma cell lines. 55, 56 In eosinophils, PGD 2 has been suggested to decrease the portion of late apoptotic eosinophils at nanomolar concentrations, 21 but to induce apoptosis in micromolar concentrations (≥10 M). 26 In the current study, we show that DP1 prolongs the survival of eosinophils by protecting the mitochondria from the onset of intrinsic apoptosis. The DP1 agonist BW245c reduced mitochondrial membrane depolarization and decreased caspase 3/7 activation while pharmacological blockade with the DP1 antagonist reversed the inhibitory action on caspase 3/7. In general, apoptosis of eosinophils can be induced intrinsically, or extrinsically mediated via Fas receptor. 57, 58 The mechanism of DP1 induced survival is consistent with the mechanism of eosinophil-specific survival stimuli, such as IL-5, 32 that has been shown to inhibit the intrinsic apoptosis pathway by activating anti-apoptotic proteins of the Bcl2 family. 59 Additionally, DP1 receptor expression promoted viability and increased the growth of PGD 2treated HEK293 monolayers. Because this finding shows that DP1 has a growth stimulating role on proliferating cells, DP1-signaling might contribute to the differentiation and growth of eosinophil progenitor cells in addition to IL-5. 60 Future experiments might therefore address the role of PGD 2 in the differentiation and proliferation of eosinophil progenitors.
Furthermore, we observed that DP1 signaling induces SRE, which in turn regulates the expression of genes that are crucial for the formation of the cytoskeleton and survival. Together with ternary complex factors, serum response factors (SRF) bind and activate SRE in the promotor of immediate early genes. Besides being crucial for the cytoskeleton integrity by regulating profilin expression, SRE activation drives anti-apoptotic proteins, such as MCL1 or Bcl-2. 40, 41, 46 In B-cells SRF is inactivated by cleavage of effector caspases in order to facilitate apoptosis pathways. 61 Interestingly, the DP2 antagonist could block DP1-mediated gene transcription but a DP2 agonist did not activate it by itself. This is consistent with our previous finding that the signaling of DP1 and DP2 is interlinked and can be different when DP1 and DP2 are expressed alone or in combination. 18 The mechanism behind PGD 2 -regulated gene transcription has remained largely unknown and it is not clear which particular DP1-or DP2-dependent pathway leads to the observed SRE induction and at which level of the cascade the interaction between DP1 and DP2 may happen. DP1 has been shown to signal via activation of G s thereby activating adenylate cyclase and raise cAMP levels. However, we previously demonstrated that DP1 cannot only couple to G s-, 62, 63 but also to the G q 18 subunit of heteromeric G-proteins. Moreover, the Ca 2+ signaling of DP2 is mediated by G i coupling, which significantly loses potency when G q is inhibited and DP1 co-expressed. 18 DP2 signaling can also be regulated by arrestins 64 but the signaling cascades that are directly activated by the G subunit linked to DP1 or DP2 have been barely investigated yet.
Moreover, we report that the DP1 agonist induced Bcl-X L mRNA upregulation and pharmacological inhibition of Bcl-X L reversed its prosurvival effect. It is known that Bcl-X L is expressed in eosinophils and contributes to the pro-survival function of IL-5 and GM-CSF, 36, 59 and is transcriptionally regulated by SRF. 46 Bcl-X L mRNA expression is upregulated in eosinophils from atopic dermatitis patients in comparison to eosinophils from healthy controls. 31 Therefore, our finding supports the significance of Bcl-X L in enhanced eosinophils survival. Polymorphisms, methylation, and expression patterns of PTGDR, the gene encoding the DP1 receptor, have been associated with asthma. 65, 66 Therefore, altered DP1 receptor signaling might be crucial in allergic inflammation. Indeed, we could show that the DP1 receptor agonist upregulated CCR3 and VLA-4 mRNA expression. Besides inducing chemotaxis toward eotaxin, CCR3 was shown to enhance eosinophil viability 49 and to be transcriptionally upregulated in allergic asthma. 67 Eosinophils bind to endothelial cells mainly via VLA-4-VCAM interaction 68 which-along with CCR3 activation-might be a critical regulator of eosinophil extravasation.
Enhanced survival of immune cells at inflammatory sites has
been observed in the following allergic conditions 6 : (i) peripheral blood eosinophils from asthmatic patients survive longer compared to eosinophils from healthy control subjects, 69 (ii) apoptosis rate of sputum eosinophils correlates with exhaled nitric oxide in asthmatic children, 70 and (iii) delayed apoptosis contributes to tissue eosinophilia in nasal polyps. 71 Moreover, there is substantial literature on the beneficial effects of the reduction of circulating eosinophils in eosinophilic asthma. 7 In fact, depletion of eosinophils by antibody-dependent cellmediated cytotoxicity (ADCC) has been recently shown to effectively improve airway resistance and disease scores in asthma patients with ≥300 eosinophils/ l blood. 72, 73 The anti-IL-5R antibody benralizumab (MEDI-563) binds to circulating eosinophils and induces apop-tosis and ADCC of eosinophils and basophils in vitro. The compound depletes human bone marrow derived mononuclear cells of eosinophil precursors and eosinophils of peripheral blood of nonhuman primates and binds to eosinophils in nonhuman primate lung tissue (bronchi, small airways, bronchial parenchyma). 74 In the present study, we observed that PGD 2 did not decrease effector caspase activity and only moderately enhanced eosinophil viability compared to the DP1 agonist, but gained in anti-apoptotic capacity when DP2 signaling was blocked by the respective antagonist. Furthermore, we confirm that the DP2 selective PGD 2 metabolite 15dPGJ 2 induces caspase activity in eosinophils in a PPAR-ɣ independent manner. 26 78, 79 However, in mice, DP1 activation was also shown to promote allergic inflammation since DP1-deficient mice have reduced number of eosinophils and cytokine levels (IL-4, IL-5, IL-13) in the BAL fluid in OVA models of experimental asthma. 13 Hence, we tested if PGD 2 receptors directly regulate survival of ex vivo differentiated murine bone marrow-derived eosinophils (bmEos).
We found that neither PGD 2 nor BW245c or DK-PGD 2 significantly changed the in vitro survival of bmEos significantly ( Supplementary   Fig. 7) . Therefore, the reported roles of DP1 in vivo could result from indirect effects mediated through other cell types such as lung dendritic cells and regulatory T-cells 71 and it is likely that the functions of DP1 differs between human and murine eosinophils. and neutrophils, to promote a Th2-type of inflammation 80 but they have also been shown to directly exert antiviral and antimicrobial host defense mechanisms and modulate the functions of lymphocytes. Thereby eosinophils support the resolution of inflammatory conditions. 81 In addition, a population of homeostatic eosinophils (hEos) that differs phenotypically and functionally from inflammatory eosinophils (iEos) has been discovered recently. hEos in the lung express genes that negatively regulate Th2 cell functions to maintain lung immune homeostasis. 82 These findings might be important to consider in a potential therapy where DP1 receptors are targeted to prevent eosinophil survival in tissues.
On the other hand, no negative side effects of eosinophil depletion by benralizumab 74 have been reported so far. Benralizumab is generally well tolerated and effective in patients with severe eosinophilic asthma. 83 Interestingly, in a recent proteome analysis DP2, cyclooxygenase-1, and prostaglandin E2 synthase, but neither DP1 nor EP2, EP4, or IP receptors were detected in peripheral blood eosinophils of allergic donors. 84 This finding confirms the low expression level of these GPCRs which we found in eosinophils from healthy donors by Western blot and flow cytometry. [85] [86] [87] In conclusion, our data demonstrate that the PGD 2 receptor DP1 has a critical role in regulating the survival of eosinophils by inhibiting the onset of the intrinsic apoptotic cascade.
Hence, PGD 2 has a dual role in allergic inflammation, that is, besides directly recruiting eosinophils to afflicted tissues, this lipid mediator might also counteract the resolution of the allergic response by prolonging the survival of eosinophils. Consequently, DP1 receptor antagonists-in addition to DP2 antagonists-or dual DP1/DP2 antagonists might be useful therapeutic tools to reduce eosinophils infiltration and activation at sites of allergic inflammation. 
